ArticleFrontiers in pharmacology2026
Cost-utility analysis of simultaneous initiation of finerenone and empagliflozin for type 2 diabetes mellitus complicated with chronic kidney disease.
Qiang Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.